,
, Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages, Blood, vol.127, issue.22, pp.2672-2681, 2016.
Recurrent BRAF mutations in Langerhans cell histiocytosis, Blood, vol.116, issue.11, pp.1919-1923, 2010. ,
Somatic activating ARAF mutations in Langerhans cell histiocytosis, Blood, vol.123, issue.20, pp.3152-3155, 2014. ,
MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis, Genes Chromosomes Cancer, vol.54, issue.6, pp.361-368, 2015. ,
Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis, Blood, vol.124, pp.3007-3015, 2014. ,
Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis, Blood, vol.128, issue.21, pp.2533-2537, 2016. ,
Diverse and targetable kinase alterations drive histiocytic neoplasms, Cancer Discov, vol.6, issue.2, pp.154-165, 2016. ,
High prevalence of BRAF V600E mutations in ErdheimChester disease but not in other non-Langerhans cell histiocytoses, Blood, vol.120, issue.13, pp.2700-2703, 2012. ,
Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders, Cancer Discov, vol.5, issue.1, pp.64-71, 2015. ,
Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations, N Engl J Med, vol.373, issue.8, pp.726-736, 2015. ,
Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation, Blood, vol.121, issue.9, pp.1495-1500, 2013. ,
Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF (V600E)-mutated Erdheim-Chester disease, J Clin Oncol, vol.33, issue.5, pp.411-418, 2015. ,
Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis, JAMA Oncol, vol.1, issue.6, pp.836-838, 2015. ,
Histiocytosis X histogenetic arguments for a Langerhans cell origin, Biomedicine, vol.18, issue.5, pp.365-371, 1973. ,
Histiocytoses: emerging neoplasia behind inflammation, Lancet Oncol, vol.18, issue.2, pp.113-125, 2017. ,
Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X?, Br J Haematol, vol.169, issue.1, pp.3-13, 2015. ,
BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups, J Exp Med, vol.211, issue.4, pp.669-683, 2014. ,
Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease, Blood, vol.124, pp.3016-3019, 2014. ,
High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis, Blood, vol.124, issue.10, pp.1655-1658, 2014. ,
Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells, J Immunol, vol.184, issue.8, pp.4557-4567, 2010. ,
Frequent clinical overlap of histiocytic neoplasms and WHO-classified myeloid malignancies leads to functional insights into the cell-of-origin of histiocytoses, Blood, vol.128, p.951, 2016. ,
Restricted dendritic cell and monocyte progenitors in human cord blood and bone marrow, J Exp Med, vol.212, issue.3, pp.385-399, 2015. ,
TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis, Cancer Cell, vol.20, issue.1, pp.25-38, 2011. ,
Femoral bone marrow aspiration in live mice, J Vis Exp, vol.89, p.51660, 2014. ,
AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3, Leukemia, vol.24, issue.10, pp.1785-1788, 2010. ,
Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny, Nat Rev Immunol, vol.14, issue.8, pp.571-578, 2014. ,
, , vol.130, pp.176-180, 2017.
,
,
,
, Zofia Hélias-Rodzewicz
,
, Information about subscriptions and ASH membership may be found online at: all rights reserved
, Hematology, 2021.
, Blood